General Surgery Clinic and Liver Transplant Center, University Hospital of Udine, Udine, Italy -
Unit of Metabolism and Nutrition, Department of Endocrinology, University Hospital of Udine, Udine, Italy.
Minerva Surg. 2021 Oct;76(5):407-414. doi: 10.23736/S2724-5691.21.08619-3. Epub 2021 Apr 23.
Immunonutrition has gained increasing interest over years, enough to be recommended in several international guidelines and to be included in the ERAS protocol for colorectal surgery. Although clinical advantages have been proved for malnourished cancer-affected patients, its role is more controversial in other settings. We evaluated the impact of immunonutrition in major colorectal elective surgery for benign and malignant diseases, regardless of the preoperative nutritional status.
We conducted a single center retrospective analysis of a database of patients who underwent elective major colon-rectal surgery for benign and malignant diseases between January 2018 and February 2020. In January 2019 we started a protocol to define which patients should receive preoperative immunonutrition, regardless of their nutritional status. We compared early postoperative outcomes and laboratory data of this group (IMN) to those of patients who met all the characteristics to be included in the protocol, but who did not receive immunonutrition (CTRL).
The IMN group showed significantly lower total leukocytes and neutrophils values and a lower pathological leukocytosis rate on 1 postoperative day compared to the CTRL group (P=0.004). Although differences in early postoperative clinical outcomes were not significant, patients belonging to the IMN group needed less postoperative antibiotic treatment (P=0.047).
Immunonutrition could affect granulocytopoiesis and neutrophils recruitment in damaged tissues. This could lead to better and faster tissue healing and, consequently, to a reduction in postoperative complications even in normo-nourished patients. The lower need for antibiotic treatment could reflect a reduced susceptibility to postoperative infections.
免疫营养近年来受到越来越多的关注,已被多项国际指南推荐,并被纳入结直肠手术的 ERAS 方案中。尽管已证明免疫营养对营养不良的癌症患者有临床获益,但在其他情况下其作用仍存在争议。我们评估了免疫营养在结直肠择期手术中的作用,无论患者术前营养状况如何,这些手术都涉及良性和恶性疾病。
我们对 2018 年 1 月至 2020 年 2 月间在我们中心行择期结直肠手术的良性和恶性疾病患者的数据库进行了单中心回顾性分析。2019 年 1 月,我们开始了一项方案,以确定哪些患者应接受术前免疫营养,无论其营养状况如何。我们比较了该组(IMN 组)与那些符合方案纳入标准但未接受免疫营养的患者(CTRL 组)的早期术后结果和实验室数据。
与 CTRL 组相比,IMN 组患者术后第 1 天的总白细胞和中性粒细胞值较低,且病理性白细胞增多的发生率较低(P=0.004)。尽管术后早期临床结果的差异无统计学意义,但 IMN 组患者需要较少的术后抗生素治疗(P=0.047)。
免疫营养可能影响受损组织中的粒细胞生成和中性粒细胞募集。这可能导致更好、更快的组织愈合,从而降低术后并发症的发生率,即使是在营养状况正常的患者中也是如此。抗生素治疗需求的降低可能反映了术后感染易感性的降低。